- Report
- December 2024
- 125 Pages
Global
From €4232EUR$4,650USD£3,628GBP
- Report
- October 2024
- 190 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- March 2025
- 200 Pages
Global
From €2266EUR$2,490USD£1,943GBP
- Report
- April 2025
- 93 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- April 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- February 2025
- 150 Pages
Global
From €2729EUR$2,999USD£2,340GBP
- Report
- May 2024
- 140 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 128 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 138 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 138 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 137 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 140 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- October 2024
- 212 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- April 2025
- 200 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Clinical Trials
- August 2024
- 60 Pages
Global
From €1365EUR$1,500USD£1,170GBP
- Report
- October 2024
- 250 Pages
Global
From €4504EUR$4,949USD£3,861GBP
- Report
- May 2024
- 200 Pages
Global
From €3777EUR$4,150USD£3,238GBP
- Report
- September 2024
- 253 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- June 2024
- 174 Pages
Asia Pacific
From €1365EUR$1,500USD£1,170GBP

Memantine is a drug used to treat symptoms of Alzheimer's disease and other forms of dementia. It is classified as an NMDA receptor antagonist, which works by blocking the action of a neurotransmitter called glutamate. This helps to reduce the symptoms of dementia, such as memory loss, confusion, and difficulty with language. Memantine is also used to treat Parkinson's disease, Huntington's disease, and multiple sclerosis.
Memantine is a relatively new drug, having been approved by the FDA in 2003. It is available in both oral and intravenous forms, and is typically prescribed in combination with other drugs. It is generally well-tolerated, with few side effects.
The memantine market is a growing one, with a number of companies offering products. These include Novartis, Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Other companies, such as Actavis, Lupin, and Dr. Reddy's Laboratories, also offer generic versions of the drug. Show Less Read more